Research Article of International Journal of Traditional and Complementary Medicine
Preparation and characterization of curcumin-loaded silica nanoparticles and their in-vivo anti-cancer activity evaluation
Sonia Tyagi1, Deepak Yadav2, and Javed Abrar Farooqi1*
1School of Sciences, Indira Gandhi National Open University, New Delhi, India
2Miranda House College, University of Delhi, New Delhi, India
Curcumin [(1E,6E)-1,7-bis (4-hydroxy- 3-methoxyphenyl) -1,6- heptadiene-3,5-dione)], a polyphenolic compound derived from dietary spice turmeric, has numerous biological and pharmacological activities. It is currently being used for treating several disorders, including cancer. Keeping in view its importance, the curcumin was embedded in the silica nanoparticles prepared by reaction of Tween-40, n-Butanol, triethoxyvinylsilane and 3-aminopropyltriethoxysilane using water as solvent. After completion of reaction, the nanoparticles were obtained by dialysis of the reaction mixture. The nanoparticles were characterized by SEM, TEM, DLS and XRD analyses. The SEM, TEM and DLS analysis shows the average particle size to be 70nm, 66 nm and 75.72nm respectively. Further in-vivo studies were conducted on wistar rats to determine the maximum tolerance dose (MTD) of nanoparticles and study the anti-cancer potential by tumor regression analysis. The MTD was found to be 10 mg/kg body weight of wistar rats and curcumin-doped ORMOSIL nanoparticles in comparison with pure curcumin revealed the highly significant results in tumor regression in EAT induced tumor model.
Keywords: Silica nanoparticles, curcumin and EAT tumor model
How to cite this article:
Sonia Tyagi, Deepak Yadav, and Javed Abrar Farooqi.Preparation and characterization of curcumin-loaded silica nanoparticles and their in-vivo anti-cancer activity evaluation. International Journal of Traditional and Complementary Medicine 2020, 5:20.
1. Aggarwal BB, Kumar A, Bharti A.C, 2003, Anticancer research.23:363-398.
2. Aggarwal BB, Sundaram C, Malani N, Ichikawa H (2007), Adv Exp.Med.Biol.595:1-75.doi:10.1007/978-0-387-46401-5_1.PMID 17569205.
3. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB, (2007), Mol. pharmaceutics, Vol.4, NO.6, 807-818.
4. Cheng A.L, Hsu C.H, Lin J.K, et al, 2001, Anticancer research.21:2895-2900.
5. Cheng A.L, Hsu C.H, Lin J.K, Hsu M.M, Ho Y.F, Shen T.S, Ko J.Y, Lin J.T, lin B.R, Ming-Shiang W, Yu H.S, Jee S.H, Che G.S, Chen T.M, Chen C.A, Lai M.K, Pu Y.S, Pan M.H, Wang Y.J, Tsai C.C, Hsieh C.Y (2001), Anticancer Res., 21 (4B), 2895-500.
6. Dinda A.K; Prashant C.K; Naqvi S; Unnithan J; Samim M; Maitra A , Int. J. of Nanotechnology, 2012 Vol.9, No.10/11/12, pp.862 – 871.
7. Lao D.C, Demierre M.F, Sondak V.K (2006) , Expert rev. Anticancer Ther. 6 (11), 1559-68.
8. Lao D.C, Ruffin M.T, Normolle D, Heath D.D, Murray S.I, Bailey J.M, Boggs M.E, Crowell J, Rock C.L, Brenner D.E (2006) , BMC Complement Altern. Med., 6,10.
9. Peter J. Neumann, Jennifer A. Palmer, Eric Nadler, ChiHui Fang, Peter Ubel doi: 10.1377/hlthaff.2009.0077Health Aff , January 2010 vol. 29 no. 1196-202
10. Ruby, A.J, Kuttan G, Babu K.D, Rajasekharan K.N, Kuttan R (1995),Cancer Lett., 94(1), 79-83.
11. Shanker T.N, Shantha N.V, Ramesh H.P, Murthy I.A, murthy V.S (1980), Ind. j. Exp. Biol. 18 (1), 73-5.
12. Sharma, O.P. (1976) , Biochem. Pharmacol., 25 (15), 1811-1812.
13. Shishodia S, Sethi G, Aggarwal BB (2005), Ann.N.Y.Acad.Sci.1056:206-217.doi: 10.1196/annals.1352.010.
14. Shoba G, Joy D, Joseph T, Majeed M,Rajedra R, Srinivas P.S (1998), Planta Med, 64 (4), 353-6.
15. Srimal R.C, Dhawan B.N (1973) , J.Pharm. Pharmacol., 25 (6), 447-52.
16. Sugiyama Y, Kawakishi S, Osawa T (1996) , Biochem. Pharmacol., 52 (4), 519-25.
17. Valadares MC, Klein SI, Queiroz ML., Eur J Pharmacol 2004; 503:203–208.
18. Vos T, Caracoti A, Che J, Dai M, Farrer C, Forsyth N, et al., J Med Chem. 2004; 47:1602–4.
19. Yadav D, Anwar MF, Garg V, Kardam H, Beg MN, Suri S, Gaur S, Asif M., As Pac J Can Prev 2014; 15(5):2335-2340.
This work and its PDF file(s) are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.